Clorox (CLX) Q4 EPS Jumps 58%

Clorox reported Q4 FY2025 results that significantly beat analyst expectations, with adjusted EPS reaching $2.87 and revenue $1.99 billion. However, this outperformance was primarily driven by a one-time boost from incremental ERP-related shipments, which management estimates added $0.85-$0.95 to EPS and 13-14 percentage points to sales, masking underlying soft core demand. Consequently, the company issued a cautious FY2026 outlook, forecasting a 6-10% sales decline and an 18-23% drop in adjusted EPS to $5.95-$6.30, as these temporary benefits reverse and new cost pressures, including tariffs, take effect.

Analysis

Clorox reported a significant Q4 FY2025 earnings beat, with adjusted EPS of $2.87 and revenue of $1.99 billion surpassing consensus estimates. However, this outperformance is entirely attributable to a one-time pull-forward of shipments ahead of an ERP system upgrade, which management quantified as contributing $0.85 to $0.95 to EPS and 13 to 14 percentage points to sales growth. Excluding this temporary effect, underlying organic sales were flat, indicating soft consumer demand. The primary takeaway is the exceptionally weak guidance for FY2026, which projects a 6% to 10% decline in net sales and an 18% to 23% drop in adjusted EPS to a range of $5.95 to $6.30. This forecast reflects the full reversal of the ERP-related gains, coupled with new headwinds including $100 million in annualized cost pressure from tariffs and an expected gross margin compression of 50 to 100 basis points. Despite the company's strong brand portfolio and innovation pipeline, the near-term outlook is dominated by these operational normalization challenges and escalating cost pressures.

Key Decisions for Investors

• Investors should look past the Q4 FY2025 headline beat, as it was driven by temporary shipment timing and masks flat underlying demand, and instead focus on the severe FY2026 guidance which points to a significant contraction.
• It is critical to model for lower profitability in FY2026, incorporating management's guidance for a 50 to 100 basis point gross margin compression and new cost pressures from $100 million in tariffs.
• Any share price strength following the Q4 results should be treated with caution, as the forward-looking fundamentals are overwhelmingly negative and likely to weigh on valuation throughout the coming fiscal year.